The randomized, double blind, placebo-controlled study, which was performed in collaboration with the University of Vermont University of Medicine, was made to examine the result of adding daily chromium picolinate supplementation to regimens consisting of oral antidiabetic medicines, i.e. Sulfonylureas. Specifically, a sulfonylurea, a frequently prescribed first line of treatment for type 2 diabetes, was given to 27 subjects primarily for a three-month period. The subjects were then randomized to continue taking the medication only for 6 additional weeks with or without chromium picolinate.This difference may show that the cannabis-user group did not possess the same mental propensity for psychosis. Related StoriesUnited Cannabis files utility and PCT patent applications related to unique specifications of cannabinoidsStudy shows prevalence of marijuana make use of and marijuana make use of disorders on the rise in U.S.MSU professor finds surprising outcomes about drug use behaviors ‘While mind activity for both groupings was related, there are subtle differences between schizophrenia sufferers with a brief history of cannabis use and those who have never used cannabis.